Corbion Under Pressure: A Decline in Q1, but a Rebound Expected from Q2
Corbion, the group listed on Euronext Amsterdam and specializing in sustainable ingredients, is experiencing a temporary contraction phase. The first quarter of 2026 saw a confirmed decline in revenue and results compared to the same period last year. Beyond these declines, margins also suffered from significant compression. However, this cyclical deterioration hides a scheduling logic: the company anticipates a restart from Q2, sufficient to meet its annual targets.
Q1 2026: A Period of Negative Growth
Corbion recorded negative growth in the first quarter of 2026, both in terms of sales and results. According to Olivier Rigaud, the company's CEO, this decline is due to two factors: on one hand, a particularly high comparison from the first quarter of 2025 for the Functional Ingredients & Solutions division, and on the other hand, an expected phasing of the Nutrition segment in 2026. This phasing is not presented as an anomaly, but as a planned variation in the year's schedule. The group emphasizes that this Q1 weakness should be viewed in the context of a full year whose distribution is not uniform across the quarters.
Impact on Profitability
The impact on profitability is more significant. Adjusted EBITDA margins fell by 360 basis points in the first quarter, a contraction mainly attributed to product mix effects and a low operational leverage related to the temporarily depressed sales in the Health & Nutrition segment. In response to this compression, Corbion has decided to immediately launch a cost reduction program, with effects beginning to materialize from the second quarter. This swift management response aims to preserve the guidance on adjusted EBITDA margins for the entire year.
Anticipated Strengthening of Sales
The group anticipates a strengthening of sales in the Health & Nutrition division starting from the second quarter, a restart that management considers sufficient to compensate for the weakness of Q1 and more than make up for the gap over the year. Corbion also expects a return to positive growth in volume and mix during the remaining quarters. Under these conditions, the company asserts it remains on track to deliver its 2026 guidance on all forecast indicators: sales growth, adjusted EBITDA margins, and free cash flow. The management notes that macroeconomic and geopolitical uncertainties, particularly the conflict in the Middle East, create pricing and supply chain challenges that the teams are actively managing. The main challenge for investors lies in the effective restart of Nutrition from Q2, a key condition for meeting the annual guidance.
